Soderling E, Le Bell A, Kirstila V, Tenovuo J. Betaine-containing toothpaste relieves subjective symptoms of dry mouth. Acta Odontol Scand 1998;56:65-9.
LoVecchio F, Curry SC, Bagnasco T. Butyrolactone-induced central nervous system depression after ingestion of RenewTrient, a dietary supplement. N Engl J Med 1998;339:847-8.
FDA. FDA warns about products containing gamma butyrolactone or GBL and asks companies to issue a recall. Talk Paper, 21 January 1999.
Tunnicliff, G. Sites of action of gamma-hydroxybutyrate (GHB)-a neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997;35:581-90.
Anon. Adverse events associated with ingestion of gamma-butyrolactone--Minnesota, New Mexico, and Texas, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:137-40.
Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-4.
Anon. FDA alert on misuse of consumer products containing GHB, GBL and BD. Food and Drug Administration, Rockville, MD. June 15, 1999.
Anon. Important message for health professionals: Report serious adverse events associated with dietary supplements containing GBL, GHB or BD. Food and Drug Administration, Rockville, MD. August 25, 1999. Available at: https://vm.cfsan.fda.gov/~dms/mwgblghb.html
Hillory J. Farias and Samantha Reid date-rape drug prohibition act of 2000. 106th Congress of the United States of America. HR 2130.
Anon. Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. JAMA 1991;265:447-8.
Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol 1992;23:1027-34.
Carotenuto A, De Feo V, Fattorusso E, et al. The flavonoids of Allium ursinum. Phytochem 1996;41:531-6.
FDA Talk Paper. FDA Warns About GBL-Related Products. 1999. Available at: vm.cfsan.fda.gov/~lrd/tpgbl2.html
Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent (abstract). Neurosci Biobehav Rev 1994;18:291-304.
Maitre M. The gamma-hydroxybutyrate signaling system in brain: organization and functional implications (abstract). Prog Neurobiol 1997;51:337-61.
Feigenbaum JJ, Howard SG. Gamma hydroxybutyrate is not a GABA agonist (abstract). Prog Neurobiol 1996;50:1-7.
Mamelak M. Gammahydroxybutyrate: an endogenous regulator of energy metabolism (abstract). Neurosci Biobehav Rev 1989;13:187-98.
Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men (abstract). J Clin Invest 1997;100:745-53.
Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. J Forensic Sci 1995;40:501-4.
Ellinwood EH Jr, Gonzalez AE, Dougherty GG Jr. Gamma-Butyrolactone effects on behavior induced by dopamine agonists (abstract). Biol Psychiatry 1983;18:1023-32.
Dougherty GG, Ellinwood EH Jr. Influence of gamma-butyrolactone on behavior due to dopaminergic drugs (abstract). Physiol Behav 1983;30:607-12.
Snead OC III, Bearden LJ. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate (abstract). Neurol 1980;30:832-8.
Kohrs FP, Porter WH, et al. Gamma-hydroxybutyrate intoxication and overdose. [Letter and responses]. Ann Emerg Med 1999;33:475-6.
Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001;21:31-3..
Sivilotti ML, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001;38:660-5..
Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med. 2001;344:87-94..
Mason P, Kerns II W. Gamma Hydroxybutyric Acid (GHB) Intoxication. Acad Emerg Med 2002;9:730-39..
Bosch OG, Eisenegger C, Gertsch J, et al. Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology. 2015 Dec;62:1-10.
Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006 Oct;26(5):524-9.
Weiss T, Müller D, Marti I, Happold C, Russmann S. Gamma-hydroxybutyrate (GHB) and topiramate--clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration. Eur J Clin Pharmacol. 2013 May;69(5):1193-4.
Bhattacharya IS, Watson F, Bruce M. A case of ?-butyrolactone associated with severe withdrawal delirium and acute renal failure. Eur Addict Res 2011;17(4):169-71.
Corkery JM, Loi B, Claridge H, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 2015;53:52-78.
Dargan PI, Button J, Davies S, et al. The first reported UK fatality related to gamma-butyrolactone (GBL) ingestion. J R Soc Med 2009;102(12):546-7.
Eiden C, Capdevielle D, Deddouche C, et al. Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal.
J Addict Med 2011;5(4):302-3.
Heytens L, Neels H, Van Regenmortel N, et al. Near-fatal persistent anion- and osmolal-gap acidosis due to massive gamma-butyrolactone/ethanol intoxication. Ann Clin Biochem 2015;52(Pt 2):283-7.
Roberts DM, Smith MW, Gopalakrishnan M, et al. Extreme ?-butyrolactone overdose with severe metabolic acidosis requiring hemodialysis. Ann Emerg Med 2011;58(1):83-5.
Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of ?-hydroxybutyrate, ?-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 2012;50(6):458-70.
van Gerwen M, Scheper H, Touw DJ, van Nieuwkoop C. Life-threatening acute lung injury after gamma butyrolactone ingestion. Neth J Med 2015;73(3):133-5.
Zepf FD, Holtmann M, Duketis E, et al. A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. Pharmacopsychiatry 2009;42(5):202-3.
Product information for Xyrem. Jazz Pharmaceuticals, Inc. Palo Alto, CA. March 2022.
Delic M. Inpatient management of GHB/GBL withdrawal. Psychiatr Danub. 2019 Sep;31(Suppl 3):354-356.
van Helmond LPFM, Gresnigt FMJ. Safety of withholding intubation in gamma-hydroxybutyrate- and gamma-butyrolactone-intoxicated coma patients in the emergency department. Eur J Emerg Med. 2020 Jun;27(3):223-227.
Delcourt N, Lanot T, Vardon-Bounes F, Gandia P, Franchitto N. Severe metabolic failures after recreational ingestion of ?-butyrolactone. J Clin Psychopharmacol. 2020 Nov/Dec;40(6):624-626.